Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BIO.B Stock Forecast 2026-2027
$310.70
Current Price
$9.72B
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BIO.B Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BIO.B Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-8.9%
1 Year Change
0.0%
Year-to-Date Change
-13.5%
From 52W High of $359.22
+37.9%
From 52W Low of $225.29
📊 TOP ANALYST CALLS
Did BIO.B Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bio-Rad is one of their latest high-conviction picks.
Latest BIO.B Stock Price Targets & Analyst Predictions
BIO.B has shown a year-to-date change of 0.0% and a 1-year change of -8.9%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BIO.B. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO.B Analyst Ratings
0
Buy
0
Hold
0
Sell
BIO.B Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $310.70
Latest BIO.B Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.B.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 30, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $340.00 |
| Oct 30, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $375.00 |
| Aug 1, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $265.00 |
| Aug 1, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $409.00 |
| Jun 9, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $245.00 |
| May 2, 2025 | UBS | Dan Leonard | Buy | Maintains | $310.00 |
| May 2, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $392.00 |
| May 2, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $350.00 |
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $270.00 |
| Feb 12, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $345.00 |
| Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
| Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
| Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
| Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
| Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
| Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
| Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
| Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 |
Bio-Rad Laboratories, Inc. (BIO.B) Competitors
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories, Inc. (BIO.B) Financial Data
Bio-Rad Laboratories, Inc. has a market capitalization of $9.72B with a P/E ratio of 29.0x. The company generates $2.56B in trailing twelve-month revenue with a -26.4% profit margin.
Revenue growth is +0.5% quarter-over-quarter, while maintaining an operating margin of +10.4% and return on equity of -9.5%.
Valuation Metrics
Market Cap
$9.72B
Enterprise Value
$8.36B
P/E Ratio
29.0x
PEG Ratio
N/A
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+0.5%
Gross Margin
+52.6%
Operating Margin
+10.4%
Net Margin
-26.4%
EPS Growth
+0.5%
Financial Health
Cash/Price Ratio
+16.9%
Current Ratio
5.4x
Debt/Equity
20.7x
ROE
-9.5%
ROA
+1.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bio-Rad Laboratories, Inc. (BIO.B) Business Model
About Bio-Rad Laboratories, Inc.
What They Do
Develops advanced analytical and diagnostic technologies.
Business Model
Bio-Rad Laboratories generates revenue by creating and selling innovative analytical and diagnostic tools for life sciences and clinical diagnostics. Their product offerings, such as PCR instruments and chromatography systems, cater to a diverse range of industries including healthcare and research, ensuring a steady demand for their solutions.
Additional Information
Founded in 1952, Bio-Rad has established itself as a leader in its field, providing essential products for genomics, proteomics, and food safety applications. The company is recognized for its commitment to scientific advancement, making it a reliable partner in both research and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,700
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1999
Website
www.bio-rad.comBio-Rad Laboratories, Inc. (BIO.B) Latest News & Analysis
Latest News
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
5 months ago
Quick Summary
The U.S. plans a 40% NIH budget cut in 2026, potentially impacting Bio-Rad's operations. The company anticipates 0.5% revenue growth for 2025, with mixed valuations indicating fair value.
Why It Matters
A 40% budget cut to the NIH may hinder Bio-Rad's growth potential, reflected in its modest revenue projections. Mixed valuation results indicate uncertainty surrounding its investment appeal.
Source: Seeking Alpha
Market Sentiment:
Negative
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
5 months ago
Quick Summary
Bio-Rad Laboratories, Inc. (BIO) reported second-quarter financial results that exceeded expectations.
Why It Matters
Better-than-expected financial results from Bio-Rad may signal strong demand and operational efficiency, potentially boosting investor confidence and stock performance.
Source: Benzinga
Market Sentiment:
Positive
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
1 year ago
Quick Summary
Bio-Rad Laboratories reported Q3 profit surpassing Wall Street estimates, driven by increased demand for analytical tools from biotech clients and consistent growth in clinical diagnostics sales.
Why It Matters
Bio-Rad's stronger-than-expected profits signal robust demand in biotech and clinical diagnostics, suggesting potential growth and stability in the sector, which could positively influence investor sentiment.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Bio-Rad Laboratories has reduced its annual revenue growth forecast due to decreased demand for clinical diagnostics products from biotech clients.
Why It Matters
Bio-Rad's lowered revenue growth forecast signals declining demand in the biotech sector, potentially impacting its stock price and overall market confidence in the diagnostics industry.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Bio Rad Laboratories confirmed its 2024 sales growth forecast despite ongoing weak spending from biotech firms and sluggish demand in China.
Why It Matters
Weak spending by biotech firms and sluggish demand in China could hinder Bio Rad's growth, potentially impacting its stock performance and investor sentiment.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Bio-Rad Laboratories reduced its annual revenue growth forecast due to uncertainty in the biopharma sector, causing shares to drop approximately 11% in after-hours trading.
Why It Matters
Bio-Rad's lowered revenue forecast signals potential weaknesses in the biopharma sector, impacting investor confidence and resulting in a significant share price drop.
Source: Reuters
Market Sentiment:
Negative
Frequently Asked Questions About BIO.B Stock
What is Bio-Rad Laboratories, Inc.'s (BIO.B) stock forecast for 2026?
Analyst forecasts for Bio-Rad Laboratories, Inc. (BIO.B) are not currently available. The stock is trading at $310.70.
Is BIO.B stock a good investment in 2026?
Analyst ratings for BIO.B are not currently available. The stock is currently trading at $310.70. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIO.B stock?
Price predictions from Wall Street analysts for BIO.B are not currently available. The stock is trading at $310.70.
What is Bio-Rad Laboratories, Inc.'s business model?
Bio-Rad Laboratories generates revenue by creating and selling innovative analytical and diagnostic tools for life sciences and clinical diagnostics. Their product offerings, such as PCR instruments and chromatography systems, cater to a diverse range of industries including healthcare and research, ensuring a steady demand for their solutions.
What is the highest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $310.70.
What is the lowest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $310.70.
What is the overall BIO.B consensus from analysts for Bio-Rad Laboratories, Inc.?
Analyst ratings for BIO.B are not currently available. The stock is trading at $310.70.
How accurate are BIO.B stock price projections?
Stock price projections, including those for Bio-Rad Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 6:51 AM UTC